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vation, which may play
a role in its clinical
efficacy.
Daratumumab (DARA) has shown impressive activity in combination with other agents for
the treatment ofmultiplemyeloma (MM).We conducted a phase 1b study to assess the safety
and preliminary efficacy, as well as potential mechanisms of action, of DARA (16 mg/kg)
in combination with a weekly schedule of subcutaneous bortezomib (1.3-1.5 mg/m2),
cyclophosphamide (150-300 mg/m2), and dexamethasone (40 mg) (CyBorD DARA) as initial
induction before autologous stem cell transplantation (ASCT). Eligible patients were
#70 years of age with untreated MM requiring treatment and who lacked significant
comorbidities. A total of 18 patients were enrolled. Their median age was 56 years (range,
32-66 years), and all patients had Eastern Cooperative Oncology Group performance
status #1. The International Staging System stages were I, II, and III in 78%, 17%, and 6% of
patients, respectively; 28% of patients had high-risk genetic features. There was no dose-
limiting toxicity, and the incidence of grade 3 or 4 infection or neutropenia was ,10%.
On an intention-to-treat basis, 94% achieved $very good partial response with $complete
response in 44% of patients. Among 14 of 15 patients who underwent ASCT and were
evaluable for response, all 14 achieved at least very good partial response, with 8 (57%) of 14
achieving complete response. After ASCT, 10 (83%) of 12 patients in whomminimal residual
disease analysis was possible were negative at a sensitivity of 1025 (56% on intention-to-
treat/whole study population) according to next-generation sequencing. Flow cytometry
analysis of patient samples indicated CyBorD DARA induced activation of macrophage-
mediated antibody-dependent cellular phagocytosis. This trial was registered at
www.clinicaltrials.gov as #NCT02955810.
Introduction
Daratumumab (DARA), a human immunoglobulin G 1 kappa (IgG1k) monoclonal antibody with single-
agent activity in multiple myeloma (MM), exhibits strong synergy in combination with other anti-MM
agents, including immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). As previously
reported in four phase 3 studies, the addition of DARA to standards of care in both relapsed refractory or
transplant-ineligible patients with newly diagnosed MM resulted in a $45% reduction in the risk of
disease progression or death.1-4 Thus, there is considerable interest in exploring DARA in combination
with existing regimens for fit, transplant-eligible patients in whom induction followed by high-dose
therapy with autologous stem cell transplantation (ASCT) is currently the standard of care.5 Based on
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response rates, depth of response, and progression-free survival as
surrogate markers for outcome, 3-drug combinations including
a PI and dexamethasone are currently the standard of care before
ASCT.6 Given recent impressive results with triplet regimens
incorporating a PI and an IMiD in induction, it is generally accepted
that a PI/IMiD combination constitutes the ideal backbone with
which to combine DARA before ASCT. Conversely, cyclophospha-
mide, a drug commonly used in the treatment of MM, is frequently
partnered with monoclonal antibodies in approved regimens for the
treatment of hematologic malignancies. Indeed, cyclophosphamide
has been shown to induce an acute secretory activating phenotype,
releasing chemokines and cytokines from treated tumor cells, which
in turn induce macrophage infiltration and phagocytic activity in the
bone marrow.7 After the generation of preliminary data indicating
that cyclophosphamide may have the potential to enhance DARA
macrophage-mediated antibody-dependent cellular phagocytosis
(ADCP), we hypothesized that the addition of DARA to weekly
CyBorD, a widely used combination of bortezomib, cyclophospha-
mide, and dexamethasone, may provide a convenient and well-
tolerated alternative, IMiD-free option.8,9 Weekly (as opposed to
twice weekly) administration of bortezomib is reportedly associated
with a much lower risk of grade 3 peripheral neuropathy, without
sacrificing efficacy, which has led to its widespread adoption.5,10
This finding provided the rationale for a phase Ib trial of CyBorD in
combination with DARA (#NCT02955810). Our objectives were to
determine the preliminary safety and efficacy of this combination in
newly diagnosed MM patients eligible for ASCT, with the additional




Eligible patients were #70 years of age and had untreated MM
requiring treatment as per the revised International Myeloma
Working Group criteria, along with measurable disease. Key
inclusion criteria were Eastern Cooperative Oncology Group
performance status #2, hemoglobin level $7.5 g/dL, absolute
neutrophil count $1.0 3 109/L, platelet count $70 3 109/L,
adequate liver function, and calculated creatinine clearance level
$40 mL/min/1.73 m2. Key exclusion criteria comprised confirmed
amyloidosis, known chronic obstructive pulmonary disease with
a forced expiratory volume in 1 second ,50% of predicted normal,
history of moderate or severe persistent asthma or uncontrolled
asthma at the time of screening, HIV positivity, hepatitis B or C virus
positivity, history of significant other malignancy, significant
concurrent uncontrolled medical illness, and grade 2 or higher
peripheral neuropathy (National Cancer Institute Common Toxicity
Criteria Version 4.0). All patients provided written informed consent.
The study was approved by the Irish Health Products Regulatory
Authority and local hospital ethics committee according to the
requirements of Irish regulations, and it was conducted in accor-
dance with the International Conference on Harmonisation of Good
Clinical Practice Guidelines and the principles of the Declaration
of Helsinki.
Study Design
This phase Ib, open-label, single-arm, dose escalation study was
conducted at 3 separate centers within Blood Cancer Network
Ireland. The study was designed to assess the safety and efficacy of
4 cycles of induction therapy with oral (by mouth) cyclophospha-
mide and subcutaneous bortezomib on days 1, 8, 15, and 22;
dexamethasone 20 mg by mouth on days 1, 2, 8, 9, 15, 16, 22, and
23; and DARA 16 mg/kg IV on days 1, 8, 15, and 22 for cycles 1
and 2 and on days 1 and 15 for cycles 3 and 4. After induction
therapy, patients proceeded to stem cell mobilization and high-dose
melphalan 200 mg/m2 IV followed by ASCT. After ASCT, 2 cycles
of consolidation therapy with cyclophosphamide and bortezomib
on days 1, 8, 15, and 22, dexamethasone 20 mg on days 1, 2,
8, 9, 15, 16, 22, and 23, and DARA 16 mg/kg on days 1 and 15
were administered. After consolidation therapy, all patients were
scheduled to receive DARA maintenance therapy on day 1 every
4 weeks until progression, unacceptable toxicity, or withdrawal of
consent (maximum duration of 2 years). Patients with high-risk
disease as defined by International Staging System (ISS) stage III
and/or high-risk cytogenetic findings, including t(4;14), t(14;16),
and del17p, received subcutaneous bortezomib on days 1 and 15
during the maintenance phase in addition to DARA. We used
a standard 3 1 3 design in sequential cohorts, 3 dose levels of
cyclophosphamide and bortezomib: dose level 1, cyclophospha-
mide 150 mg/m2 and bortezomib 1.3 mg/m2; dose level 2,
cyclophosphamide 300 mg/m2 and bortezomib 1.3 mg/m2; dose
level 3, cyclophosphamide 300 mg/m2 and bortezomib 1.5 mg/m2;
and a dose level 21, cyclophosphamide 100 mg/m2 and
bortezomib 1.3 mg/m2. Six additional patients were enrolled in an
expansion cohort at the maximum tolerated dose, once this dose
was determined.
The study’s primary end points were the incidence of dose-limiting
toxicity within the first cycle of combination at each dose level and
complete response (CR) rate post-ASCT (assessed 30-60 days
after ASCT). Dose-limiting toxicity was defined as any of the
following treatment-emergent adverse events occurring during the
first cycle (within 28 days from the first dose) of treatment and
possibly, probably, or definitely related to the combination of
CyBorD plus DARA: prolonged grade IV hematologic toxicity lasting
.7 days, febrile neutropenia (absolute neutrophil count ,0.5 3
109/L and fever .38.5°C) that persists for .48 hours despite
adequate treatment with antibiotics and/or antifungal/antiviral
agents, treatment delay due to toxicity that persists .42 days after
the start of cycle 1, clinically significant grade 3 or 4 non-
hematologic toxicity (including peripheral neuropathy), dose mod-
ifications, or missed dose during cycle 1. Secondary end points
include: safety, CR rates at the end of induction, consolidation and
maintenance, best overall response, minimal residual disease
(MRD) negative rate as assessed by using next-generation
sequencing (NGS), progression-free survival, clinical benefit rate,
and overall survival. Responses were investigator assessed as per
the International Myeloma Working Group criteria. To correctly
characterize response and mitigate DARA interference in patients
with IgGk MM, the HYDRASHIFT 2/4 assay (Sebia) was used. All
registered patients were included in the intention-to-treat (ITT) and
safety analyses. This trial is registered at www.clinicaltrials.gov as
NCT02955810.
Translational studies
To gain mechanistic insights into the mechanism of action of the
combination of CyBorD with DARA, consenting patients were enrolled
into a translational substudy. Briefly, peripheral blood (PB) and bone
marrow samples were collected pretreatment and posttreatment with
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CyBorD and DARA; samples were then analyzed for cell number,
phenotype, and serum cytokines. Full details of the methods are
available in the supplemental Materials and methods.
Results
Patient characteristics and disposition
Eighteen patients were enrolled between November 2016 and
December 2017 with a median follow-up of 16.8 months (Table 1).
Baseline characteristics were as follows: median age, 56 years
(range, 32-66 years); 61% male, 39% female; Eastern Cooperative
Oncology Group performance status 5 0, 1 in 50% each; and ISS
stages I, II, and III in 78%, 17%, and 6% of patients, respectively.
Twenty-eight percent of patients were identified with high-risk
genetic features [t(4;14), t(14;16), and del17p by using fluores-
cence in situ hybridization and/or gene expression profiling [GEP]
using SKY92 (SkylineDx)]. Three patients discontinued therapy
early (primary refractory, persistent liver toxicity, and death, respec-
tively), and 1 patient relapsed from CR while undergoing mainte-
nance therapy.
Safety
Overall, treatment was well tolerated. During the dose escalation
phase (n 5 12), gastrointestinal side effects related to CyBorD
were the most common nonhematologic adverse event (nausea,
66%; diarrhea, 66%; and constipation, 40%). The majority of these
were less than grade 2 severity. The only adverse events higher than
grade 3 severity occurring in .5% of patients within the dose
escalation phase were lymphopenia (16%), urinary tract infection
(16%), and back pain (16%). Five serious adverse events were
reported, but none was related to study treatment. No patient
experienced DLT, and the maximum tolerated dose of the
combination was therefore set as cyclophosphamide 300 mg/m2
and bortezomib 1.5 mg/m2 in combination with DARA and
dexamethasone. Across the entire study, the most common grade
3/4 hematologic treatment-emergent related adverse events were
lymphopenia (22%) and neutropenia (6%). The most common
grade 3/4 nonhematologic treatment-emergent related adverse
events were diarrhea (11%) and neutropenic sepsis (6%) (Table 2).
One patient died of grade 5 diffuse alveolar damage 7 weeks’ post-
ASCT, and this death was not believed to be related to CyBorD
DARA treatment. The patient had a history of heavy cigarette
smoking before diagnosis, which may have predisposed toward
pneumonitis. No definite infectious etiology, including viral infection,
was implicated. In the expansion phase, a single patient developed
Table 1. Patient characteristics and response data
Age, y Sex ISS FISH SKY92
Response MRD post-ASCT
PETInduction ASCT 1024 1025 1026
1 35 Male I del17p, del1p, 213 SR VGPR CR Neg Neg Neg Neg
2 57 Male II HD, 1q1 SR CR CR Neg Neg Ind Neg
3 60 Male I t(11;14) SR VGPR CR Neg Neg Ind Neg
4 56 Female I HD, del13q SR VGPR Failed PBSC mobilization NA NA NA NA
5 60 Male I IgH, 213 SR VGPR VGPR* NA NA NA Neg
6 58 Male I del17p, 1q1, HD SR VGPR RIP† NA NA NA NA
7 42 Male I HD SR Partial response VGPR Neg Neg Ind Neg
8 66 Male I HD SR Partial response VGPR Pos Pos Pos Neg
9 54 Male I Abnormal IgH, 1q1 SR VGPR CR Neg Neg Ind Neg
10 46 Male II HD, 1q1 SR VGPR CR Neg Neg Neg Neg
11 64 Female I Failed SR CR CR NA NA NA Neg
12 65 Female I HD SR Partial response VGPR Neg Neg Neg Neg
13 66 Female I 213,1q1, HD SR Partial response CR Neg Neg Ind Neg
14 48 Female I t(4;14), 1q1, HR Partial response VGPR Neg Pos Pos Neg
15 52 Male III t(11;14) HR Refractory NA NA NA NA NA
16 63 Male II HD SR VGPR VGPR Neg Neg Pos Neg
17 50 Female I t(14;16), 213, 11q HR VGPR CR Neg Neg Ind Neg
18 32 Female I IgH,-13 SR VGPR‡ NA NA NA NA NA
FISH, fluorescence in situ hybridization; HD, hyperdiploidy; HR, high risk; NA, not applicable; PBSC, PB stem cell; RIP, death/died; SR, standard risk.
*Measurable disease serum-free light chain (SFLC). Normalization of value of involved FLC but abnormal SFLC ratio due to suppressed uninvolved SFLC.
†Died of bilateral pneumonitis. MRD negative postinduction at $1024.
‡Came off study after 3 cycles.
Table 2. Toxicities related to study treatment
Treatment-emergent toxicities of ‡grade 3 severity related
to study treatment Total (N 5 18)
Gastrointestinal Diarrhea 2
Infection Sepsis 1





25 JUNE 2019 x VOLUME 3, NUMBER 12 CyBorD DARA IS EFFECTIVE INDUCTION IN MM 1817
.For personal use only on September 11, 2019. at UNIVERSITY COLLEGE CORK www.bloodadvances.orgFrom 
grade 3 liver toxicity, which was asymptomatic. The causality of this
toxicity is uncertain. Viral serology results for hepatitis A, B, and C
were negative. The patient had a background of mild nonalcoholic
fatty liver disease, and the first cycle of treatment was complicated
by influenza, which coincided with transaminitis 2 to 3 weeks into
treatment. This fluctuated between grade 2 and 3 severity and
persisted despite holding therapy. Results of a liver biopsy revealed
mild nonspecific changes only. DARA-associated infusion reactions
were grade 2 or lower (11%).
Response
On ITT analysis, 94% achieved $very good partial response
(VGPR) with $CR in 44% of patients. The overall response rate
postinduction therapy was 94% (17 of 18) with achievement of
$VGPR in 67% of patients (12 of 18). Among the 16 patients
completing 4 cycles of induction, $partial response rate post-
induction was 100%, $VGPR (69%), and $CR (13%). Two
patients did not complete all 4 cycles of induction. One of these
patients proved refractory to treatment and discontinued due to
progressive disease during cycle 4. The second patient discon-
tinued after 3 cycles due to persistent grade 3 elevation of
transaminase levels. Informative NGS data (Adaptive Biotechnolo-
gies) were available on 10 of 18 patients achieving .VGPR
postinduction, all of whom were MRD-negative postinduction at
a sensitivity level of 1024, with 2 patients MRD negative at a level of
1025 and 1 patient MRD negative at a level of 1026.
Sixteen of 18 patients underwent PB stem cell mobilization with
cyclophosphamide and granulocyte colony-stimulating factor. In
addition, 4 patients (25%) received plerixafor at the discretion of
their physician. PB stem cell harvests were successful in 94% of
patients (15 of 16) with a sufficient number of CD341 cells
collected for ASCT. One patient, who had extensive spinal
irradiation at diagnosis, failed repeated attempts at stem cell
mobilization. This patient did not proceed to ASCT; however,
because the patient seemed to be benefiting from therapy, she
went on to receive consolidation and maintenance therapy. The
median number of CD341 cells harvested was 6.46 3 106/kg
(range, 0.7-13.36 3 106/kg; SD, 62.74). All patients success-
fully harvested proceeded to ASCT, and all were successfully
engrafted with a median time to neutrophil recovery .0.5 3 109
and to platelets .20 3 109 of 10.5 days (range, 10-12 days; SD,
60.79) and 15 days (range, 11-14 days; SD, 62.15), re-
spectively (full data were only available for 12 of 15 patients).
These data are similar to those previously reported in trials using
CyBorD as induction therapy before ASCT.1,2 They also compare
favorably with other trials incorporating novel agents in the
upfront setting.3
One patient died before the post-ASCT response assessment.
Thus, 14 of 15 patients are evaluable for response post-ASCT.
Responses deepened post-ASCT, with all 14 patients achieving
$VGPR (94% on ITT) and 57% achieving $CR (44% on ITT).
Post-ASCT positron emission tomography/computed tomography
scans were consistent with complete metabolic response in all
14 patients. After ASCT, there was considerable upgrading of
response. MRD analysis was possible in 12 of 14 patients
(Table 3). In the remaining 2 patients, the diagnostic samples
failed to calibrate. Excluding patients who were in VGPR post-
ASCT but in whom MRD analysis was not possible, 10 (83%) of
12 patients were negative at 1 in 105 (56% on ITT). At a sensitivity
of 1026, 3 (25%) were negative and 6 (50%) were indeterminate,
with only 3 patients (25%) positive at this level. Following
consolidation, 8 of 18 (44%) patients were MRD negative at
a level of 1025 with 10 of 18 (56%) negative at 1024 (Table 3). At
last follow-up 14 patients remained on study without disease
progression.
To explore the hypothesis that CyBorD DARA would lead to
increased tumor infiltration by activated macrophages leading to
a more robust antitumor immune response, we collected PB and
bone marrow samples from consenting patients (n 5 12) at
baseline and 24 hours after starting treatment with CyBorD
DARA.
CyBorD DARA rapidly deplete natural killer cells
without affecting macrophage numbers in the
bone marrow
CD38 is expressed at high levels on myeloma cells and on natural
killer (NK) cells at higher levels than other immune cells,11 resulting
in NK cell depletion after DARA treatment.12 To assess whether
CyBorD DARA could affect macrophage activation and function
in vivo, multiparameter flow cytometry was used to quantify the
number of mononuclear cells in patient bone marrow samples
before and 24 hours after treatment (Figure 1A-B). In line with
previous studies,12 we found rapid depletion of lymphocytes
(Figure 1C, left panel) as early as 24 hours’ posttreatment. We
also observed an increase in neutrophils (Figure 1C, middle panel)
but no significant change in the numbers of monocytes in the bone
marrow of treated patients (Figure 1C, right panel). On analysis of
specific lymphocyte subpopulations (supplemental Figure 1),13 we
validated that the reduction of lymphocytes was specific to NK cells
in MM patient bone marrow (Figure 1D, right panel) as neither
CD31 CD41 T cells nor CD31 CD81 T-cell numbers were
changed (Figure 1D, left and middle panels). We observed similar
trends in PB mononuclear cells (Figure 2A), with rapid depletion of
lymphocytes in PB samples after treatment. We also observed an
increase in neutrophils (Figure 2B, middle panel) similar to that seen
in bone marrow samples. In contrast to bone marrow, a significant
reduction in monocytes occurred in the PB of treated patients
(Figure 2B, right panel). NK cell depletion was validated in MM
patient PB mononuclear cells (Figure 2C, right, left and middle
panels). Collectively, our results indicate that macrophages, in
contrast to NK cells, are unaffected by CyBorD DARA treatment.
Macrophages in the tumor microenvironment in MM and the
interaction with DARA could be harnessed to potentiate antitumor
functions.








ITT (n 5 18) ,1025 2/18 (11%) 10/18 (56%) 8/18 (44%)
,1026 1/18 (6%) 3/18 (17%) 3/18 (17%)
Evaluable* (n 5 12) ,1025 2/12 (15%) 10/12 (83%) 8/12 (67%)
,1026 1/12 (8%) 3/12 (25%) 3/12 (25%)
ITT, intention-to-treat.
*Patients who achieved $ VGPR after completion of ASCT and with MRD results
available.
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CyBorD DARA induces expression of Fcg receptor 1
on patient-derived monocyte/macrophage cells
We next determined changes in macrophage activation after
treatment with CyBorD DARA. Monoclonal antibodies can control
tumor growth through mechanisms that include antibody-dependent
cellular cytotoxicity (ADCC) and ADCP.14,15 ADCP is triggered
through interaction of the antibody Fc domain with the Fcg receptors
(FcgRs) expressed on NK cells, neutrophils, and macrophages. We
therefore assessed macrophage receptor expression of CCR2,
CD16 (FcgRIII), CD32 (FcgRII), CD64 (FcgR1), and PD-1, receptors
that can mediate effector functions such as ADCP.16,17 Using an
optimized gating strategy,18 we identified monocytes/macrophages
in bone marrow and PB mononuclear cell samples as CD451,
CD141, CD331, and CX3CR11 cells (Figure 3A). We assessed
a panel of activation receptors on macrophages in the bone marrow
and PB, including CCR2, CD16, CD32, and PD-1. No changes in
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Figure 1. Bone marrow mononuclear cell numbers in patients with MM before and after cyclophosphamide treatment. (A) Absolute numbers of the 3 major bone
marrow subtypes were quantified by using flow cytometry in bone marrow samples from 10 adults diagnosed with MM before (pretreatment) and 24 hours after (posttreatment)
with CyBorD DARA. (B) Specific CD451 bone marrow subpopulations were identified based on side scatter characteristics and surface expression of CD14. Representative
gating strategy for bone marrow aspirates for the identification and quantification of lymphocytes, neutrophils, and monocytes. (C) Graphed dot plots indicate the absolute
number of lymphocytes, neutrophils, and monocytes from bone marrow aspirates before (prescreened) and 24 hours’ posttreatment with CyBorD DARA (n 5 10). (D) Dot
plots indicate the absolute number of CD41 and CD81 T cells and NK cells pretreatment and posttreatment (n 5 6). Gating for subpopulation of lymphocytes is shown in
supplemental Figure 1. Lines between dots indicate paired samples. Wilcoxon matched pairs signed rank test and paired Student t tests were used to detect statistically
significant differences between pretreatment and posttreatment samples. *P , .05, **P , .01. FSC-A, forward scatter–area; ns, not significant; SSC-A, side scatter–area.
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either the bone marrow or PB of MM patients posttreatment. We
next assessed receptors involved in macrophage-mediated
phagocytosis, FcgR1 (or CD64) and signal regulatory protein-
a (SIRP-a). No significant difference was observed in the
expression of SIRP-a (supplemental Figure 2). Significant
increases were observed in CD64 expression on macrophages
posttreatment. Interestingly, these significant changes were
observed in the bone marrow and PB, where we show an
increase in CD64 expression by histogram (Figure 3B), and
these changes were significant across the 10 independent
samples analyzed (P , .01). CD64 mediates IgG1-specific
ADCC/ADCP with highest affinity and transduces most stimu-
latory phagocytosis signals in macrophages.19 The enhanced
macrophage CD64 expression in PB may serve as a noninvasive
marker of macrophage ADCP activation (Figure 3C).
CyBorD DARA induces secretion of proinflammatory
and suppresses anti-inflammatory mediators of
macrophage function in patient serum
Macrophage phenotype, activation, and function are regulated by
signals in the microenvironment.20 We next determined the levels
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PBMC sample
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Figure 2. PB mononuclear cell (PBMC) numbers in patients with MM before and after cyclophosphamide treatment. (A) Absolute numbers of the 3 major PB
subtypes were quantified by using flow cytometry in blood samples from 10 adults diagnosed with MM before (pretreatment) and 24 hours after (posttreatment) with CyBorD
DARA. Specific CD451 PB subpopulations were identified based on side scatter characteristics and surface expression of CD14 (as in Figure 1B). (B) Graphed dot plots
indicate the absolute number of lymphocytes, neutrophils, and monocytes from bone marrow aspirates before (prescreened) and 24 hours’ posttreatment with CyBorD DARA
(n 5 10). (C) Dot plots indicate the absolute number of CD41 and CD81 T cells and NK cells pretreatment and posttreatment (n 5 6). Gating for subpopulation of
lymphocytes is shown in supplemental Figure 1. Each dot represents an individual patient. Lines between dots indicate paired samples. Wilcoxon matched pairs signed rank test
and paired Student t tests were used to detect statistically significant differences between pretreatment and posttreatment samples. *P , .05, **P , .01, ****P , .001. ns, not
significant.
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of both proinflammatory and anti-inflammatory cytokines in
patient serum(Figure 4). Levels of proinflammatory cytokine tumor
necrosis factor-a (TNF-a) and interferon-g (IFN-g) and anti-
inflammatory molecules interleukin-10 and prostaglandin E2
(PGE2) were next assessed. Although the overall levels of
circulating cytokines were low, a significant increase was
observed in the levels of both TNF-a and IFN-g in serum 24 hours
after treatment (Figure 4). Of note, neither TNF-a nor IFN-g was
detectable in healthy control serum samples. There were no
significant changes in either interleukin-10 or PGE2 after
treatment. These results indicate that circulating proinflammatory
cytokines are present at higher levels posttreatment and may
contribute to macrophage activation.
CyBorD DARA reduces CD47 expression on
patient-derived CD1381 MM cells
Because CD64 has a major role in macrophage-mediated ADCP,
we next assessed tumor cells for the expression of ligands that
negatively regulate phagocytosis through the receptors PD-1 and
SIRP-a, PD-L1 and CD47, respectively (Figure 5A). PD-L1 binding
with PD-1 has also been implicated in regulation of macrophage-
mediated phagocytosis.17 CD47 binds SIRP-a, resulting in in-
hibition of phagocytosis, and is recognized as the “don’t eat me
signal” that is upregulated on tumor cells as an immune evasion
strategy.21 We observed no changes in PD-L1 on MM cells after
























































































Figure 3. Multicolor flow cytometry for the identifi-
cation and expression of CD64 on PB and bone
marrow monocyte subsets. (A) Representative dot
plots are shown to illustrate the gating strategy for the
identification of total monocytes. Monocytes were identi-
fied by CD331CX3CR1CD56–CD141 expression.
(B) Representative histogram of CD64 expression on
CD331CX3CR1CD56-CD141 bone marrow monocytes/
macrophages from a patient with MM pretreatment and
posttreatment. The black histogram is the fluorescence
minus one control (FMO). The gray filled histogram
identifies the pretreatment bone marrow sample, and the
dotted line represents the posttreatment bone marrow
sample (left). Dot plots indicate the mean fluorescence
intensity of CD64 expression pretreatment and
posttreatment on CD331CX3CR1CD56–CD141
monocytes/macrophages (n 5 13) (right). (C) Represen-
tative histogram of CD64 expression on
CD331CX3CR1CD56–CD141 PB monocytes/macro-
phages from a patient with MM pretreatment and
posttreatment. The black histogram is the FMO. The gray
filled histogram identifies the pretreatment PB sample,
and the dotted line represents the posttreatment PB
sample (left). Dot plots indicate the mean fluorescence
intensity of CD64 expression pretreatment and posttreat-
ment on CD331CX3CR1CD56–CD141 PB monocytes/
macrophages (n 5 13) (panel B, right). Lines between
dots indicate paired samples. Wilcoxon matched pairs
signed rank test and paired Student t tests were used to
detect statistically significant differences between
pretreatment and posttreatment samples. *P , .05,
**P , .01. APC, allophycocyanin; FSC-H, forward
scatter–height; MFI, mean fluorescence intensity; SSC,
side scatter.
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observed in CD47 expression on CD1381 MM cells after treatment
(n 5 5; P , .05). The downregulation of CD47 expression on
CD1381 MM cells was only significant in the bone marrow
(Figure 5B, left), at the tumor site, and not in the PB of patients
with MM (Figure 5B, right). These results suggest that MM cells
after treatment with CyBorD DARA may be more susceptible to
phagocytosis in the tumor microenvironment.
Discussion
The addition of DARA to CyBorD in the current study did not
increase toxicity compared with that previously reported with
CyBorD alone.9,22 In addition, the tolerability of CyBorD DARA
compares favorably with previous reports of other frontline DARA-
containing regimens. In the ALCYONE study, 39.9% of patients in
the DARA group experienced .grade 3 neutropenia, compared
with 6% with CyBorD DARA.3 In the MAIA study, 50% of patients in
the DARA group experienced grade 3 and higher neutropenia.
However, it should be recognized that both of these studies
involved the treatment of an older, transplant-ineligible population,
who may be more susceptible to toxicity. The rate of grade 3 or 4
infections was 23.1% in the DARA group, with pneumonia (13.7%)
the most common grade 3 or 4 infection.4,5 In the current study, 2
patients discontinued treatment because of adverse events.
Given the small patient numbers, the results of the current study
should be interpreted with caution. However, they compare
favorably with results of similar regimens in the frontline setting
and suggest that the addition of DARA to CyBorD is likely to be
beneficial, inducing better responses in the absence of significant
added toxicity. Up to 60% of patients would be expected to achieve
$VGPR after 4 cycles of induction with CyBorD.9 Consistent with
this, in a single institutional experience we observed $VGPR in
56% after 4 cycles of induction, which increased to 79% post-
ASCT, with 24% of patients achieving CR post-ASCT.22 However,
in the current study, with the addition of DARA (ITT analysis), 94%
and 44% of patients achieved VGPR and CR after ASCT,
respectively, with 57% of patients evaluable for response post-
ASCT achieving CR. Our results also compare favorably with
another widely used standard of care, lenalidomide, bortezomib,
and dexamethasone. In the IFM2009 trial, the rate of VGPR/CR in
the transplant arm was 47% after induction, which increased to
70% post-ASCT.23 Results of LYRA, a phase 2 study evaluating
CyBorD DARA in a community setting, were recently published.24 In
this study, after 4 induction cycles, investigators observed $VGPR
in 44% (primary end point) of patients newly diagnosed with MM,
with an overall response rate of 79%, which is lower than that
previously reported with CyBorD alone. In the current study, the rate
of VGPR and the overall response rate for all patients at the end of 4
cycles was 67% (12 of 18) and 94% (17 of 18). MRD data were not
reported for the LYRA study. It is possible that the patients enrolled
in the LYRA study had a higher risk profile than our study. For
example, 36.6% of newly diagnosed patients enrolled in the LYRA
study had high cytogenetic risk. In the recent publication, the
authors also speculated that conduct of this study in a community
setting may have affected the observed response rates. Finally,
although unlikely to have greatly influenced the differences
observed between the 2 studies, patients in the LYRA study
received bortezomib on days 1, 8, and 15 only, whereas our patients
received bortezomib on days 1, 8, 15, and 22, every 28 days.
What is most encouraging, however, is the depth of response
achieved in the majority of patients in the current study. Ten (56%)
of 18 patients achieved MRD negativity at a level of sensitivity of
1025 within 30 to 60 days after ASCT, with 3 patients (25%)
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Figure 4. Analysis of circulating proinflamma-
tory and anti-inflammatory cytokines in MM
patient serum before and after treatment with
CyBorD DARA. (A) Representative scheme to
illustrate the work flow for isolation and analysis of
patient serum before and after treatment. (B) Dot
plots indicate the levels of TNF-a (upper left, n 5
12), IFN-g (upper right, n 5 12), interleukin-10
(IL-10) (lower left, n 5 12), and PGE2 (lower right,
n 5 12) before and after treatment in MM serum
samples. Lines between dots indicate paired sam-
ples. Paired Student t tests were used to detect
statistically significant differences between pre-
treatment and posttreatment samples. *P , .05.
ELISA, enzyme-linked immunosorbent assay.
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already negative at a level of 1026. By comparison, in the MAIA
study, after a median follow-up of 28 months, 24% of patients
achieved MRD negativity at a level of 1025.4
In reported clinical trials, longer overall survival was observed
among patients in whomMRD is undetectable compared with those
in whom MRD can be detected, regardless of the treatment given;
as such, the achievement of MRD negativity is considered an
important treatment target in MM. In the IFM2009 study, patients
who were MRD negative at a level of sensitivity of at least 1026 had
a higher probability of prolonged progression-free survival than
patients with detectable residual disease, regardless of cytogenetic
risk profile or ISS disease stage at diagnosis.23 In the IFM2009
study, 79% of patients in the transplant arm achieved MRD
negativity at a sensitivity 1024; by NGS, however, MRD negativity
(sensitivity of 1026) was achieved at least once during maintenance
in only 25% of patients.25 It should be noted that the International
MyelomaWorking Group guidelines recommend an MRD sensitivity
threshold of 1025 (not 1026) when using NGS or the next-
generation flow approach, and thus it is appropriate to use this level
when comparing data from different studies.26
Not all patients in the current study benefited, however. One patient
who had ISS stage III disease was primary refractory to treatment,
with evidence of progressive renal impairment with a rise in
creatinine from normal at baseline to .200 mmol/L, along with
a significant increase in involved serum-free light chains during the
fourth cycle of induction. Results of a renal biopsy were consistent
with cast nephropathy, and the patient was taken off study. GEP
using SKY92 can identify patients at high risk of progression, and
this patient was identified as high risk according to GEP at
baseline.27 A total of 3 patients were identified with high-risk GEP at
baseline by SKY92, of whom only 1 patient managed to achieve
MRD negativity at a level of 1025. One patient, who had high-risk
fluorescence in situ hybridization as well as high-risk GEP, achieved
VGPR post-ASCT and was MRD negative at a level of 1024 only.
Despite double maintenance with bortezomib and DARA, this
patient’s disease progressed within 10 months of ASCT. Although
our data are limited, it suggests that in the presence of high-risk
GEP, even a potent quadruplet regimen such as CyBorD DARA
may be insufficient to overcome drug resistance. Whether this
theory will be borne out with greater experience and whether PI/
IMiD DARA combinations would be any more effective in this
respect remains to be seen.28
From the CASTOR study, it is known that bortezomib is synergistic
with DARA.1 What then is the likely contribution of cyclophospha-
mide to our regimen? With progression to MM, there are an
increasing number of tumor-associated macrophages (TAMs) in the
bone marrow.29 These are predominantly of an M2 phenotype,
which promotes tumor survival and immune suppression leading to
disease progression and inferior survival. A predominance of M2
macrophages as well as T-cell exhaustion have been linked to
resistance to DARA/IMiD combinations.30 Although TAMs are
generally considered to be undesirable, under certain circum-
stances, it is possible to harness their antitumor potential. Indeed,
macrophages are believed to be critical effectors of monoclonal
antibody therapy, and their depletion has been associated with
reduced in vivo efficacy of antibodies.31 This finding may be
particularly important in the context of DARA, which leads to rapid
depletion of CD38-positive NK cells, lasting up to 6 months after the
cessation of treatment.12 Therefore, to maximize the effect of
DARA, a sufficient number of activated TAMs may be required. We
hypothesized, based on previous research, that we could achieve
this goal by using cyclophosphamide.7 DARA has Fc-dependent
immune effector mechanisms, such as complement-dependent
cytotoxicity, ADCC, and ADCP. Inhibition of ectoenzymatic function
and direct apoptosis induction may also contribute to the efficacy of
the antibodies to kill MM cells. The CD38 antibodies also improve
host antitumor immunity by the elimination of regulatory T cells,
regulatory B cells, and myeloid-derived suppressor cells.11 Given
DARA-mediated NK cell depletion, ADCC may play a lesser role
than originally thought. As alternate effector cells, this suggests an
























































Figure 5. Multicolor flow cytometry for the identification and expression of
CD47 on plasma cells pretreatment and posttreatment with CyBorD DARA.
(A) Representative dot plots are shown to illustrate the gating strategy for the
identification of CD138 plasma cells. Plasma cells were identified by surface
expression of CD138. (B) Dot plots indicate the mean fluorescence intensity (MFI)
of CD47 expression pretreatment and posttreatment on CD138 MM cells from the
bone marrow (n 5 5) (left) and PB (n 5 5) (right). Lines between dots indicate
paired samples. Wilcoxon matched pairs signed rank test and paired Student t tests
were used to detect statistically significant differences between pretreatment and
posttreatment samples; *P , .05.
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of activated TAMs may be required to maximize the effect of DARA
in vivo. We believe our data indicate that CyBorD DARA leads to
monocyte/macrophage-mediated enhanced ADCP and a switch of
macrophages from a tumor-promoting to an antitumor, proinflam-
matory phenotype.32
Aside from its alkylating effect, cyclophosphamide has important
immunomodulatory effects with low doses able to selectively
eliminate regulatory T cells leading to immune activation.33 In
several studies in MM, the addition of cyclophosphamide led to
remarkable improvements in outcome.34-36 Analyzing patient bone
marrow samples, we observed a significant reduction in CD47, the
“don’t eat me antigen” on MM cells, and an increase in CD64 on
bone marrow macrophages, suggesting a more activated pheno-
type, 24 hours after CyBorD exposure. These findings suggest
that MM cells may be more vulnerable to phagocytosis by
macrophages after treatment with cyclophosphamide and DARA.
In conjunction with this scenario, we observed a significant increase
in the levels of both TNF-a and IFN-g in serum 24 hours after
treatment, consistent with a proinflammatory, antitumor response.
In conclusion, we present the first results combining CyBorD with
DARA in the transplant setting. Our results indicate this regimen to
be highly active and well tolerated, with a potentially unique
mechanism of action. In our view, it deserves further evaluation as
an induction regimen in the treatment of patients newly diagnosed
with MM who are eligible for ASCT. A randomized trial comparing
CyBorD DARA vs a combination of bortezomib, thalidomide, and
dexamethasone is planned.37
Acknowledgments
The authors thank the patients who participated in the CyBorD
DARA study and their families, the study coinvestigators, research
nurses, and coordinators at each of the clinical sites.
This study was supported by clinical trial and research funding
from Janssen Research & Development. Grant support to M.O. was
providedbyScience Foundation Ireland and the IrishCancer Society
(14/ICS/B3042 Blood Cancer Network Ireland), and grant support
to A.E.R. was provided by the IrishCancer Society (CRF12RYA) and
Science Foundation Ireland (15/SIRG/3456) andGalway University
Foundation. All flow cytometry experiments were performed in the
NUI Galway Flow Cytometry Core Facility, which is supported by
funds from NUI Galway, Science Foundation Ireland, the Irish
Government’s Programme for Research in Third Level Institutions,
Cycle 5, and the European Regional Development Fund.
Authorship
Contribution: M.O., R.H., M.R.C., P.M., V.M., J.Q., C.M., J.K., J.W.,
E.L., T.K., A.H., G.H., I.P., E.K., and G.G. contributed to the accrual
and treatment of patients and data acquisition, interpretation, and
analysis; A.E.R., S.D.N., R.H., A.N., K.L., and M.O. contributed to
translational study data acquisition, interpretation, and analysis; and
M.O. andA.E.R. wrote themanuscript and approved the final version.
Conflict-of-interest disclosure: M.O. and A.E.R. received re-
search support from Janssen Pharmaceuticals. M.O. and J.Q. have
received consultancy fees from Janssen and AbbVie. The remaining
authors declare no competing financial interests.
ORCID profiles: M.O., 0000-0002-6173-7140; V.M., 0000-
0002-9937-4306; A.N., 0000-0003-4321-9005.
Correspondence: M. O’Dwyer, Department of Hematology,
University Hospital Galway, Newcastle Rd, Galway H91 NH7V,
Ireland; e-mail: michael.odwyer@nuigalway.ie.
References
1. Palumbo A, Chanan-Khan A, Weisel K, et al; CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl
J Med. 2016;375(8):754-766.
2. Dimopoulos MA, San-Miguel J, Belch A, et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed
or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 2018;103(12):2088-2096.
3. Mateos MV, Dimopoulos MA, Cavo M, et al; ALCYONE Trial Investigators. Daratumumab plus bortezomib, melphalan, and prednisone for untreated
myeloma. N Engl J Med. 2018;378(6):518-528.
4. Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):
2104-2115.
5. Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
2017;28(suppl 4):iv52-iv61.
6. Moreau P. How I treat myeloma with new agents. Blood. 2017;130(13):1507-1513.
7. Pallasch CP, Leskov I, Braun CJ, et al. Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell. 2014;156(3):590-602.
8. Rigalou A, Ryan A, Natoni A, Chiu C, Sasser K, O’Dwyer ME. Potentiation of anti-myeloma activity of daratumumab with combination of
cyclophosphamide, lenalidomide or bortezomib via a tumor secretory response that greatly augments macrophage-induced ADCP. Blood. 2016;
128(22):2101.
9. Reeder CB, Reece DE, Kukreti V, et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.
Blood. 2010;115(16):3416-3417.
10. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116(23):4745-4753.
11. Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD381 immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in
multiple myeloma. Blood. 2016;128(3):384-394.
1824 O’DWYER et al 25 JUNE 2019 x VOLUME 3, NUMBER 12
.For personal use only on September 11, 2019. at UNIVERSITY COLLEGE CORK www.bloodadvances.orgFrom 
12. Casneuf T, Xu XS, Adams HC III, et al. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple
myeloma. Blood Adv. 2017;1(23):2105-2114.
13. Slevin SM, Dennedy MC, Connaughton EP, et al. Infliximab selectively modulates the circulating blood monocyte repertoire in Crohn’s disease. Inflamm
Bowel Dis. 2016;22(12):2863-2878.
14. Weiner LM, Murray JC, Shuptrine CW. Antibody-based immunotherapy of cancer. Cell. 2012;148(6):1081-1084.
15. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10(5):317-327.
16. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science. 2005;310(5753):1510-1512.
17. Gordon SR, Maute RL, Dulken BW, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.Nature. 2017;
545(7655):495-499.
18. Naicker SD, Cormican S, Griffin TP, et al. Chronic kidney disease severity is associated with selective expansion of a distinctive intermediate monocyte
subpopulation. Front Immunol. 2018;9:2845.
19. Herter S, Birk MC, Klein C, Gerdes C, Umana P, Bacac M. Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated
phagocytosis and cytotoxicity. J Immunol. 2014;192(5):2252-2260.
20. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy [published correction appears in Immunity. 2014;41 (5):866].
Immunity. 2014;41(1):49-61.
21. Willingham SB, Volkmer JP, Gentles AJ, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.
Proc Natl Acad Sci USA. 2012;109(17):6662-6667.
22. Krawczyk J, Khan S, Ahsan B, et al. Cybord is an active, well tolerated, cost-effective induction regimen in newly diagnosed multiple myeloma—a single
centre experience. Blood. 2013;122(21):5396.
23. Attal M, Lauwers-Cances V, Hulin C, et al; IFM 2009 Study. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl
J Med. 2017;376(14):1311-1320.
24. Yimer H, Melear J, Faber E, et al. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma:
LYRA study. Br J Haematol. 2019;185(3):492-502.
25. Perrot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
Blood. 2018;132(23):2456-2464.
26. Kumar S, Paiva B, Anderson KC, et al. International MyelomaWorking Group consensus criteria for response and minimal residual disease assessment in
multiple myeloma. Lancet Oncol. 2016;17(8):e328-e346.
27. Kuiper R, van Duin M, van Vliet MH, et al. Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging
System. Blood. 2015;126(17):1996-2004.
28. Chari A, Usmani SZ, Krishnan A, et al. Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients with
newly diagnosed multiple myeloma (MMY1001): updated results from an open-label, phase 1b study. Blood. 2017;130(suppl 1):3110.
29. Panchabhai S, Kelemen K, Ahmann G, Sebastian S, Mantei J, Fonseca R. Tumor-associated macrophages and extracellular matrix metalloproteinase
inducer in prognosis of multiple myeloma. Leukemia. 2016;30(4):951-954.
30. Neri P, Maity R, Tagoug I, et al. Single cell resolution profiling defines the innate and adaptive immune repertoires modulated by daratumumab and IMiDs
treatment in multiple myeloma (MM). Blood. 2017;130(suppl 1):123.
31. Weiskopf K, Weissman IL. Macrophages are critical effectors of antibody therapies for cancer. MAbs. 2015;7(2):303-310.
32. van de Donk NWCJ, Usmani SZ. CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance. Front Immunol. 2018;9:2134.
33. Abu Eid R, Razavi GS, Mkrtichyan M, Janik J, Khleif SN. Old-school chemotherapy in immunotherapeutic combination in cancer, a low-cost drug
repurposed. Cancer Immunol Res. 2016;4(5):377-382.
34. Nijhof IS, Franssen LE, Levin MD, et al. Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in
lenalidomide-refractory multiple myeloma. Blood. 2016;128(19):2297-2306.
35. Baz RC, Martin TG III, Lin HY, et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed
refractory myeloma. Blood. 2016;127(21):2561-2568.
36. Garderet L, Kuhnowski F, Berge B, et al. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. Blood. 2018;132(24):
2555-2563.
37. European Myeloma Network. https://www.myeloma-europe.org/trials/emn-18/. Accessed 3 June 2019.
25 JUNE 2019 x VOLUME 3, NUMBER 12 CyBorD DARA IS EFFECTIVE INDUCTION IN MM 1825
.For personal use only on September 11, 2019. at UNIVERSITY COLLEGE CORK www.bloodadvances.orgFrom 
